10

September

2015

MGB Biopharma Wins Scottish Business Award

Glasgow, Scotland, 10th September 2015 – MGB Biopharma, a biopharmaceutical company developing a truly novel class of anti-infectives to address the major global problem...

Read More

21

July

2015

MGB Biopharma commences Phase I clinical trial with oral formulation of MGB-BP-3 for the treatment of multi-resistant Clostridium Difficile infections

Glasgow, Scotland, 21st July 2015 – MGB Biopharma, a biopharmaceutical company developing a truly novel class of anti-infectives, to address the major global problem...

Read More

2

June

2015

MGB Biopharma Succeeds in Developing an IV Formulation of MGB-BP-3 for the Treatment of Systemic Susceptible and Resistant Gram-positive hospital-acquired Infections

Glasgow, Scotland, 2nd June 2015 – MGB Biopharma, a biopharmaceutical company developing a truly novel class of anti-infectives, to address the major global problem...

Read More

15

May

2015

MGB Biopharma Fully Supports the Latest Report from Jim O’Neill’s Review on Antimicrobial Resistance

Glasgow, Scotland, 15th May 2015 – MGB Biopharma, a biopharmaceutical company developing a truly novel class of  anti-infectives, endorses the latest report from Jim...

Read More

24

March

2015

MGB Biopharma to Present at the Superbugs & Superdrugs Conference in London on 26th March

Glasgow, Scotland, 24th March 2015 – MGB Biopharma, a biopharmaceutical company developing truly novel anti-infectives, announces today that Dr Dawn Firmin, Head of Project...

Read More

12

January

2015

MGB Biopharma continues to progress its truly novel anti-infectives platform to tackle antibiotic resistance in 2014

Highlights In September 2014, MGB Biopharma secured £4M ($6.4M) from leading Scottish investors and Innovate UK for further clinical development of lead antibiotic MGB-BP-3...

Read More

8

December

2014

MGB Biopharma Announces Collaborations with Almac Group Ltd and Encap Drug Delivery to Manufacture Lead Antibiotic MGB-BP-3

Glasgow, Scotland, 08 December 2014 – MGB Biopharma, a biopharmaceutical company developing a truly novel class of anti-infectives, is pleased to announce that it...

Read More

1

December

2014

MGB Biopharma Nominated and Shortlisted for Scottish Enterprise Life Sciences Award

Glasgow, Scotland, 1 December 2014 – MGB Biopharma, a biopharmaceutical company developing a truly novel class of anti-infectives, announces today that it has been...

Read More

26

November

2014

MGB Biopharma in the News – European Pharmaceutical Contractor

Immediate Action: Drug-Resistant Bacteria, article written by Dr Dawn Firmin, Head of Project Management at MGB Biopharma Limited. This article was published in the December 2014...

Read More

17

September

2014

MGB Biopharma Secures £4.0m ($6.4m) to Advance its Novel Lead Antibacterial, MGB-BP-3, into Clinical Development

Glasgow, Scotland, 17 September 2014 – MGB Biopharma, a biopharmaceutical company developing a truly novel class of anti-infectives, announces today that it has secured...

Read More